ARGX (argenx SE) Moat Score: 6/10 (As of Jul. 05, 2026)


ARGX argenx SE ARGX
80 GF Score
Price $939.00
GF Value $1,382.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Moat Score?

argenx SE ARGX +3.37% 80 Moat Score is 6 as of Jul. 05, 2026. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,382.72 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,399 Biotechnology companies, argenx SE ranks better than 98.93% on this metric.

argenx SE has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

argenx SE has Narrow Moat: argenx SE has valuable intellectual property and strong R&D capabilities in the biotech sector. However, it lacks the market share and pricing power necessary for a wide moat, resulting in a strong narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes argenx SE might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

argenx SE  (NAS:ARGX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

argenx SE Moat Score Related Terms

ARGX vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, argenx SE's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Moat Score distribution charts can be found below:

* The bar in red indicates where argenx SE's Moat Score falls into.


ARGX
80GF Score
argenx SE ARGX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
argenx SE (ARGX) has a Moat Score of 6 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, argenx SE ranks #15 out of 1399 companies in the Biotechnology industry, placing it in the top 1.1%.
Is argenx SE's Moat Score too high?
argenx SE's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. argenx SE's value of 6 is 200% above this industry median. Based on the distribution chart, argenx SE ranks #15 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #15 out of 1399 companies for Moat Score. This places argenx SE in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. argenx SE's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,382.72, compared to a current price of $939.00 — trading 32.1% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For argenx SE (ARGX), the current Moat Score is 6 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $939.00 is trading 32.1% below its estimated GF Value™ of $1,382.72. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • Moat Score: 6
  • GF Value™: $1,382.72 vs. price of $939.00 (32.1% below fair value)
  • GF Score™: 80/100 with 5 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1399)

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score

Get the complete analysis for ARGX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$939.00
Price
$1,382.72
GF Value